Company intelligence / Profile preview

Cystetic Medicines

Champaign, Illinois, United Statescysteticmedicines.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has demonstrated proof-of-concept in preclinical and early clinical studies showing that their molecular prosthetic approach can restore anion transport in people with cystic fibrosis not on modulators. Their lead program, CM001, has completed dosing of healthy volunteers and initiated dosing in people with CF as part of an ongoing Phase 1 trial. Early biomarker data are promising.

Therapeutic areas: Rare Diseases
Modalities: Small molecules (specifically, small molecule ion channel prosthetics)
Industry: Biotech

Drug pipeline

1 asset

Amphotericin B cystetic for inhalation

Unknown

Partnerships

DevPro BioPharma (supporting clinical development)

Beyond the preview

Go deeper on Cystetic Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cystetic Medicines.

Explore the full profile